According to filings with the U.S. Securities and Exchange Commission, Affini-T Therapeutics is raising up to $17,617,952.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Joseph Knowles played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Affini-T Therapeutics
Affini-T is a leading clinical stage precision immunotherapy company targeting oncogenic driver mutations, beginning with KRAS, to develop potentially curative therapies for patients with solid tumors. We are advancing two distinct T Cell Receptor (TCR) based therapeutic modalities encompassing adoptive cellular therapies and bispecific T Cell Engagers, each designed to harness T cell immunity with unprecedented precision and potency against solid tumors. Our most advanced TCR T-cell therapies are built based on state-of-the-art engineering, synthetic biology, and gene editing proprietary platforms overcoming the challenges of addressing solid tumors. Our T Cell therapies have high specificity and the multi-faceted ability to strike and persist within the solid tumors. Building on the world-class innovation inherent in our leadership team, founders and differentiating technologies, we are powered to develop transformational medicines that last.

To learn more about Affini-T Therapeutics, visit http://www.affinittx.com/
Affini-T Therapeutics Linkedin Page: https://www.linkedin.com/company/affini-t-therapeutics/

Contact:
Joseph Knowles, Chief Executive Officer
617-380-3737

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.